Latest News- Microbiomes Market: Probiotics is expected to lead the Product segment during 2025-2029
The Microbiomes Market is being driven by Increasing prevalence of diseases
The Microbiomes Market is expected to grow at a CAGR of 18.3% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 824.3 million. In the dynamic microbiomes market, vendors are prioritizing strategic collaborations to gain access to advanced technologies and expedite product development. These alliances extend beyond clinical trials and research, enabling cross-selling opportunities and market expansion into untapped sectors. Notably, large pharmaceutical companies are increasingly partnering with vendors to capitalize on the high potential of microbiome therapies in treating complex diseases such as cancer and Inflammatory Bowel Disease (IBD). One recent collaboration involves Ferring Pharmaceuticals, Rebiotix, and MyBiotics, who joined forces in February 2021 to develop live microbiome-based therapeutics in reproductive medicine and maternal health.
Get more information on Microbiomes Market by requesting a sample report
Which Factors Are Causing a Surge in Market Growth?
The market is segmented based on Product (Probiotics, Foods, Prebiotics, Medical food, Others) Application (Therapeutics, Diagnostics) Geography (North America, Europe, Asia, Rest of World (ROW)).
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
Key Features in Microbiomes Market Research Report
Find out which segment is leading the market by accessing the free PDF report
The Microbiomes Market is witnessing significant innovation in therapeutics, with numerous clinical trials underway for therapeutics drugs targeting chronic diseases such as IBS and inflammatory bowel disease. Drug discovery is focused on advanced drugs like probiotics and prebiotics, personalized medicine, and fecal transplantation. The human microbiome's composition and diversity hold the key to diagnosing and treating related diseases through targeted interventions and engineering. Sequencing and manipulation of the gut microbiome are driving investment in drug development and pipeline creation. The gut-brain axis, immune system, and gut health are interconnected, and understanding their complex interactions is crucial for the future of therapeutics. Diagnostics based on microbiome testing and drug development are advancing, leading to personalized therapy and targeted interventions for various gut-related diseases. Probiotic supplements and fecal transplantation are already making an impact, but the potential for engineering and drug interactions is vast.
In the expansive realm of the global biotechnology industry, the microbiomes market occupies a significant segment. This sector encompasses businesses involved in the research and development (R&D) or production of therapeutic agents derived from the human microbiome, such as those addressing Irritable Bowel Syndrome-Diarrhea (IBS-D) and Irritable Bowel Syndrome-Constipation (IBS-C). Notable therapeutic approaches include Fecal Microbiota Therapy (FMT) and other phase I therapeutic agents. The healthcare market, a key component of the parent biotechnology industry, is poised for growth, fueled by demographic shifts. By 2050, approximately one-quarter of the US population and Europe's population by 2030 are projected to be aged 60 years or above, necessitating increased demand for medical care, drugs, and related services.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
